Novartis Launches Zero Profit Portfolio for Symptomatic Treatment of COVID-19

Shots:

• Novartis will offer a portfolio of 15 generic and OTC medicines addressing the need of low- and lower-middle-income countries to treat patients with COVID-19 symptoms. The medicines will available governments, NGOs, and other institutional customers in up to 79 countries at zero-profit to support financially strained healthcare systems
• The Novartis’ COVID-19 portfolio aid to treat gastro-intestinal illness, acute respiratory symptoms, pneumonia, and septic shock. The portfolio will be offered in addition to the Novartis Access portfolio (on- and off-patent medicines against non-communicable diseases) via the local Novartis or Sandoz affiliate
• The COVID-19 portfolio includes Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol, Vancomycin

Click here to read full press release/ article | Ref: Novartis | Image: Coroflot

Related News: Novartis Plans to Commence P-III Clinical Study Evaluating Canakinumab for Patients with COVID-19 Pneumonia